Sklamberg Quoted in Bloomberg Law on FDA Provisions in Omnibus Bill

Life Sciences and Healthcare Regulatory partner Howard Sklamberg was quoted in the recent Bloomberg Law article, “FDA Lab Test Oversight at Risk of Getting Cut From Year-End Bill.” The article discusses the possible FDA-related provisions that could be cut from the government’s year-end spending package before its passage.

Sklamberg told Bloomberg Law that retiring members have things they’d like to see included in the final bill, but they are not likely to hold up something like an omnibus to get them passed. A proposal that would have dietary supplement manufacturers registering with the FDA is likely to be cut from the omnibus bill, but provisions related to accelerated approval and clinical trial diversity mandates have a better chance of staying in the package, he said.

» Read the full article (subscription required).